What is CVE-2023-38958?

CVE-2023-38958 is a medium-severity vulnerability in Zkteco Bioaccess Ivs, classified under Incorrect Authorization. CVSS score: 5.3/10. Published 2023-08-03.

How severe is CVE-2023-38958?

Medium severity. CVSS v3 base score is 5.3 out of 10.

Auth bypass in Zkteco Bioaccess Ivs

CVE-2023-38958

An access control issue in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to arbitrarily close and open the doors managed by the platform remotely via sending a crafted web request.

Vulnerability class: Broken Access Control

Published 2023-08-03 · last modified 2026-07-09.

CVSS v3 metric

CVSS v3 base score 5.3 (Medium). Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:N.

EPSS exploit prediction

EPSS: 0.004 (28.5th percentile), scored 2026-09-30.

Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 28th percentile — 28.5% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.

EPSS over last 30 days · oldest: 0.004 · newest: 0.004 · change: +0.000

Affected products

Zkteco Bioaccess Ivs — versions 3.3.1

Weakness classification (CWE)

CWE-863 — Incorrect Authorization

References

af854a3a-2127-422b-91ae-364da2661108 (Product)
claroty.com/team82/disclosure-dashboard/cve-2023-38958 (Third Party Advisory)

Frequently asked questions

What is CVE-2023-38958?: CVE-2023-38958 is a medium-severity vulnerability in Zkteco Bioaccess Ivs, classified under Incorrect Authorization. CVSS score: 5.3/10. Published 2023-08-03.
How severe is CVE-2023-38958?: Medium severity. CVSS v3 base score is 5.3 out of 10.